Pancreatic Cancer Drug Approval Could Lift Oncology Biotech Sentiment
An FDA approval for metastatic pancreatic cancer may improve sentiment across oncology biotech, though investors still lack company-specific details.
AbbVie’s JUVMO Approval Opens New Parkinson’s Growth Opportunity for Investors
AbbVie’s FDA approval of JUVMO may expand its neurology pipeline and offer a potential diversification catalyst beyond immunology.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Spyre Therapeutics Insiders Sell More Than $3.6 Million in SYRE Stock Despite Bullish Analyst Coverage
Spyre insiders sold more than $3.6 million in SYRE stock as JPMorgan and Baird maintained bullish views, sharpening the …
MRNA’s Nasdaq-100 Inclusion Draws Retail Attention to SLS and IBRX
Moderna’s Nasdaq-100 inclusion may increase index-related attention, while retail traders compare smaller biotech names …
AbbVie Wins FDA Approval for JUVMO Parkinson’s Therapy: What ABBV Investors Should Watch
AbbVie’s FDA approval of JUVMO adds a Parkinson’s therapy to its neuroscience portfolio, but commercial execution remain…
Needham’s Buy Rating Puts LB Pharmaceuticals’ 2027 Trial Catalyst in the Spotlight
Needham’s Buy initiation highlights LB Pharmaceuticals ahead of the pivotal NOVA-2 schizophrenia readout expected in the…
Pfizer’s Tilrekimig Advances to Phase 3 as Investors Seek New Growth Drivers
Pfizer’s tilrekimig met its Phase 2 goal and is advancing to Phase 3, but the program remains an opportunity—not proof o…
AbbVie’s JUVMO Approval Puts 41% Undervaluation Thesis in Focus
AbbVie’s JUVMO approval strengthens its pipeline narrative, while Simply Wall St’s 41% undervaluation estimate remains a…
September Payrolls Miss by 61,000 as Treasury Traders Reassess Fed Rate-Cut Bets
A weak September jobs report and $60,000 two-month downward revision put Fed rate-cut expectations, Treasury yields and …
United Therapeutics Jumps 13.2% After FDA Accepts Supplemental Tyvaso Application
United Therapeutics shares traded up 13.2% after FDA acceptance of a supplemental Tyvaso application and an announced bu…
onsemi Raises Synaptics Offer to $123 a Share as Semiconductor M&A Accelerates
onsemi’s revised $123-per-share cash offer for Synaptics highlights semiconductor valuation debates and possible M&A ben…